Moneta Group Investment Advisors LLC Has $3.28 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Moneta Group Investment Advisors LLC increased its position in Pfizer Inc. (NYSE:PFE) by 4.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,052 shares of the biopharmaceutical company’s stock after buying an additional 3,246 shares during the period. Moneta Group Investment Advisors LLC’s holdings in Pfizer were worth $3,276,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. OppenheimerFunds Inc. grew its stake in Pfizer by 32.2% during the third quarter. OppenheimerFunds Inc. now owns 6,890,372 shares of the biopharmaceutical company’s stock worth $303,659,000 after buying an additional 1,678,438 shares during the period. Viridian Ria LLC grew its stake in Pfizer by 0.9% during the fourth quarter. Viridian Ria LLC now owns 30,859 shares of the biopharmaceutical company’s stock worth $1,327,000 after buying an additional 280 shares during the period. Prio Wealth Limited Partnership grew its stake in Pfizer by 3.2% during the third quarter. Prio Wealth Limited Partnership now owns 1,039,655 shares of the biopharmaceutical company’s stock worth $45,817,000 after buying an additional 32,071 shares during the period. Rehmann Capital Advisory Group grew its stake in Pfizer by 1.4% during the third quarter. Rehmann Capital Advisory Group now owns 125,426 shares of the biopharmaceutical company’s stock worth $5,528,000 after buying an additional 1,759 shares during the period. Finally, Focused Wealth Management Inc grew its stake in Pfizer by 160.7% during the third quarter. Focused Wealth Management Inc now owns 83,780 shares of the biopharmaceutical company’s stock worth $3,692,000 after buying an additional 51,644 shares during the period. 71.83% of the stock is owned by institutional investors and hedge funds.

In related news, major shareholder Pfizer Inc bought 50,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $850,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the transaction, the insider now owns 80,094 shares of the company’s stock, valued at approximately $3,524,136. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Shares of Pfizer stock traded down $0.11 during trading on Friday, hitting $43.32. 37,689,624 shares of the stock were exchanged, compared to its average volume of 21,067,500. The company has a fifty day moving average of $42.32. The stock has a market cap of $240.86 billion, a PE ratio of 14.44, a PEG ratio of 2.51 and a beta of 0.65. The company has a current ratio of 1.54, a quick ratio of 1.27 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 12 month low of $36.00 and a 12 month high of $46.47.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.75 by $0.10. The business had revenue of $13.12 billion during the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The company’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.77 earnings per share. Sell-side analysts expect that Pfizer Inc. will post 2.88 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be given a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a yield of 3.32%. Pfizer’s dividend payout ratio is presently 48.00%.

Several research analysts have recently weighed in on PFE shares. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, April 3rd. Credit Suisse Group restated a “buy” rating and issued a $48.00 target price on shares of Pfizer in a research note on Monday, June 17th. Goldman Sachs Group restated a “buy” rating and issued a $49.00 target price on shares of Pfizer in a research note on Monday, June 17th. Bank of America upped their target price on shares of Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $46.00 price target on shares of Pfizer in a report on Monday, June 17th. Thirteen investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $46.22.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Yield Curve

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.